¶ Section 242: Advanced Stem Cell Therapy and Neuronal Replacement in CBS/PSP
Stem cell therapy represents one of the most transformative approaches in neurodegenerative disease treatment, offering the potential for actual neuronal replacement rather than merely slowing degeneration. For corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), cell-based therapies aim to replace lost dopaminergic and other affected neurons, modulate the immune environment, and provide trophic support to endogenous neurons.
Unlike Parkinson's disease, where dopaminergic neuron loss is relatively focal, CBS and PSP involve more widespread neurodegeneration affecting cortical, basal ganglia, brainstem, and spinal cord regions. This creates both challenges and opportunities for cell therapy approaches.
The pathological features of CBS and PSP that make cell therapy a compelling approach include:
- Selective neuronal loss: Specific populations (dopaminergic neurons in substantia nigra, cortical neurons, brainstem nuclei) are preferentially affected, making targeted replacement feasible
- Non-cell-autonomous factors: Neuroinflammation and gliosis contribute to disease progression—MSC-based immunomodulation can address these
- Trophic factor deficiency: Endogenous neurotrophin production is impaired—cells can provide paracrine support
- 4R-tau pathology: Unlike 3R+4R tau in AD, 4R-tau in CBS/PSP may respond differently to cellular interventions
Patient-derived iPSCs can be differentiated into midbrain dopamine neurons:
- Advantages: Autologous (patient-matched), reduced immune rejection, personalized disease modeling
- Challenges: Manufacturing time (3-6 months), cost, regulatory hurdles
- Clinical status: Phase I/II trials in Parkinson's disease (Kyoto University, Nature 2025) showing 44.7% increase in putaminal dopamine
- CBS/PSP relevance: iPSC-derived neurons can model 4R-tau pathology, test patient-specific drug responses, and potentially be transplanted
Bemdaneprocel (BlueRock Therapeutics)
- Cell type: hESC-derived midbrain dopamine progenitors
- Delivery: Stereotactic transplantation to putamen
- Phase: Phase III registrational trial active
- Results: Phase I/II showed 21.9-point UPDRS improvement vs baseline
- CBS/PSP considerations: Would require modified protocols for 4R-tau environments, potentially combined with anti-tau approaches
STEM-PD (Lund University/Cambridge)
- Cell type: hESC-derived dopamine neurons
- Phase: Phase I/IIa ongoing
- Results: 100,000-200,000 surviving dopamine neurons observed post-transplantation
- CBS/PSP considerations: Safety data from this trial will inform CBS/PSP applications
MSCs provide neuroprotection through paracrine mechanisms:
- Sources: Bone marrow, umbilical cord, adipose tissue
- Delivery routes: Intravenous, intrathecal, intracerebral
- Mechanisms: Immunomodulation, trophic factor secretion (BDNF, GDNF, VEGF), anti-inflammatory effects
- Clinical trials: Safety established in PD, ALS; multiple trials active
- CBS/PSP relevance: Particularly valuable given prominent neuroinflammation in these disorders
Endogenous or derived NSCs offer multi-lineage potential:
- Potential: Replace multiple neurotransmitter systems (dopaminergic, GABAergic, glutamatergic)
- Challenges: Limited expansion capacity, migration control
- Clinical status: Early-stage; not yet in neurodegeneration trials
¶ Clinical Trial Landscape for CBS/PSP
| Trial |
Cell Type |
Phase |
Status |
Notes |
| Bemdaneprocel |
hESC-DA |
III |
Enrolling |
PD pivotal; CBS/PSP pending |
| STEM-PD |
hESC-DA |
I/IIa |
Active |
Safety/efficacy in PD |
| Kyoto iPSC-DA |
iPSC-DA |
I/II |
Completed |
44.7% dopamine increase |
| MSC trials (various) |
MSC |
I/II |
Active |
Safety focus in PD/MSA |
The putamen is the primary target for dopamine neuron transplantation:
- Rationale: Reinnervation of striatum can restore dopaminergic signaling
- Challenges: Need for long-distance axon extension in tauopathic environment
- Combined approaches: May require concurrent anti-tau therapy to protect grafts
Targeting the source rather than the target:
- Rationale: Restore the nigrostriatal pathway integrity
- Challenges: More complex surgical targeting, longer regeneration time
For CBS with prominent cortical involvement:
- Target: Motor cortex, frontal cortex
- Cell types: Cortical neuron progenitors, NSC-derived neurons
- Challenges: Cortical circuit integration, appropriate synaptic targeting
Allogeneic (Donor-derived)
- Off-the-shelf availability
- Requires immunosuppression (tacrolimus, mycophenolate)
- Risk of rejection, infection from long-term immunosuppression
- Established manufacturing processes
Autologous (iPSC-derived)
- Patient-matched, reduced rejection risk
- Complex manufacturing (3-6 months)
- Higher cost per patient
- Not yet in clinical trials for neurodegeneration
Emerging technologies to reduce immune rejection:
- HLA knockout iPSC lines
- HLA-E overexpression to evade NK cells
- Compatibility with standard immunosuppression
- Target: Putamen primarily; substantia nigra for circuit reconstruction
- Technique: Multiple injection tracks for broad coverage
- Pros: Direct delivery, high local cell concentration
- Cons: Invasive, hemorrhage risk
- Target: Systemic, with CNS migration to sites of inflammation
- Pros: Minimally invasive, repeat dosing possible
- Cons: BBB limits CNS delivery, peripheral organ trapping
- Target: CSF-exposed CNS surfaces
- Pros: Bypasses BBB, broader distribution
- Cons: Variable distribution, infection risk
| Criterion |
Score |
Notes |
| Mechanistic rationale |
8/10 |
Strong biological basis for cell replacement |
| Clinical feasibility |
4/10 |
Invasive procedures, limited CBS/PSP data |
| Safety profile |
5/10 |
Immunosuppression risks, surgical risks |
| CBS/PSP specificity |
6/10 |
Requires modification for 4R-tau pathology |
| Combination potential |
7/10 |
Synergizes with anti-tau, neurotrophin approaches |
| Evidence strength |
5/10 |
Promising in PD, limited in CBS/PSP |
| Overall |
35/60 |
58% |
- No direct interaction with stem cell therapies
- May continue standard levodopa regimen
- Post-transplant: levodopa may be reduced as graft function emerges (monitor carefully)
- No direct interaction with stem cell transplantation
- Continue preoperative regimen
- Post-operative: monitor for interactions with immunosuppressants if added
- No contraindications identified
- Immunosuppression (if allogeneic cells) requires careful drug interaction review
- Monitor liver function with tacrolimus
- Disease stage: Earlier stages (1-2) may benefit more from cell replacement
- Cognitive status: Significant cognitive impairment may affect post-surgical compliance
- Motor phenotype: CBS with prominent parkinsonism may respond better than PSP with prominent axial symptoms
- Comorbidities: Cardiovascular disease, cancer history affect eligibility
Potential benefits:
- Dopamine restoration (improved motor function)
- Neurotrophic support (slowed progression)
- Immunomodulation (reduced neuroinflammation)
Risks to consider:
- Surgical complications (hemorrhage, infection)
- Immunosuppression complications (infection, metabolic)
- Graft failure or rejection
- Potential for dyskinesias (observed in some PD trials)
- Monitor clinical trials: Track bemdaneprocel Phase III results closely
- Consider MSC therapy: Lower risk, immunomodulatory approach available in clinical settings
- Consult with transplant centers: University of Lund, Cambridge, Kyoto have active programs
- Document preferences: Advance care planning for if/when cell therapy becomes available
- Takahashi et al. Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's Disease. Nature 2025
- BlueRock Therapeutics. Bemdaneprocel Phase III Trial Update. 2024
- Lund University. STEM-PD Clinical Trial Update. 2024
- Stoker & Barker. Current status and future perspectives on stem cell-based therapies for Parkinson's Disease. J Clin Med. 2020
- Chen et al. Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives. Eur J Med Res. 2024